Australia markets open in 5 hours 40 minutes

VRTX Jan 2024 135.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
103.400.00 (0.00%)
As of 01:21PM EST. Market open.
Full screen
Previous close103.40
Expiry date2024-01-19
Day's range103.40 - 103.40
Contract rangeN/A
Open interest1
  • Motley Fool

    This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics

    In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP). The pair scored regulatory approval in the U.K. on Nov. 16 to market their first gene therapy developed in collaboration and investors have high hopes for a positive commercialization decision by the Food and Drug Administration (FDA) in the U.S. on Friday, Dec. 8. The gene therapy candidate made by Vertex and CRISPR Therapeutics is called exa-cel, and it's intended to treat sickle cell disease (SCD), a hereditary blood disorder that causes red blood cells to have a shape that's closer to a waxing crescent moon than their proper and iconic frisbee-like form.

  • Motley Fool

    5 Unstoppable Trends to Invest $1,000 in for 2024

    These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.

  • Zacks

    Why Is Vertex (VRTX) Down 6.4% Since Last Earnings Report?

    Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.